Kimberly Espinosa

Kimberly Espinosa serves as a key procurement professional within the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS), supporting the agency’s mission to accelerate the translation of scientific discoveries into clinical applications. She manages a diverse portfolio of acquisitions centered on advanced laboratory technologies, high-throughput screening systems, and automated analytical platforms critical to translational research. Her work directly enables the deployment of tissue chip systems, precision metabolite synthesis tools, and next-generation bioreactor technologies, ensuring that NCATS maintains cutting-edge capabilities in drug discovery and biological candidate evaluation. She typically handles complex, technology-driven contracts requiring specialized technical evaluation and compliance with federal research procurement standards. Espinosa cultivates strategic partnerships with a broad spectrum of vendors, including analytical instrument manufacturers, biotechnology R&D firms, and independent testing laboratories. While no single contractor dominates her portfolio, she consistently engages with firms capable of delivering customized, high-precision equipment and services aligned with NIH’s rigorous scientific requirements. Her contracting approach emphasizes performance-based specifications and agile acquisition pathways to support rapid innovation cycles, fostering collaborative relationships with both established industry players and emerging innovators in life sciences. Her procurement patterns reflect a strong preference for open competition, with 82.3% of awards issued without set-asides. Nevertheless, she actively supports small business participation, allocating 16.7% of contracts to total small business set-asides under FAR 19.5 and 1.0% to women-owned small businesses, demonstrating a balanced commitment to socioeconomic goals without compromising technical rigor. Espinosa’s primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing) and 325414 (biological product manufacturing), with significant activity in 541380 (testing laboratories) and 541714 (biotechnology R&D). She specializes in acquiring automated analytical systems, microfluidic platforms, and specialized reagents for high-content screening, reflecting deep expertise in the technical domains of translational biomedicine and laboratory automation.